January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
Archived Content

Antibodies for the 21st Century 

Innovating antibody therapeutics requires novel discovery platforms, computational insights, and engineering enhanced properties, such as binding specificity, PK and half-life.  This meeting focuses on the strategies and technologies used in the highly complex efforts to manipulate antibodies for creating next-generation therapeutics. Join with key leaders from around the world in a relaxed, congenial atmosphere to discuss the latest advances in the development of therapeutic antibodies.

Day 1 | Day 2 | Download Brochure 


1:30 pm Conference Registration

2:00 BuzZ Session A 

2:45 Refreshment Break in the Exhibit Hall with Poster Awards

3:30 - 4:15 BuzZ Session B 


7:00 am Conference Registration

7:30 Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee


Designing the Next Generation 

8:15 Chairperson's Opening Remarks

Marina Roell, Ph.D., Director, Molecular Interactions & Research Informatics, XOMA (US) LLC


Potent Antibody Drugs by Design

Paul CarterPaul Carter, Ph.D., Senior Director, Antibody Engineering, Genentech, Inc.Biography 

Antibodies have become a clinically important class of drugs as judged by 27 antibody therapeutics marketed in the USA.  Antibody therapeutics are also commercially important with ~$38 billion in worldwide sales in 2009.  This presentation will focus on strategies to create even better next-generation antibody drugs, which is a major area of interest in the field.  The impetus to develop improved antibody therapeutics comes from a convergence of clinical, scientific, and commercial considerations in conjunction with technological advances that provide the tools to do so.

» 9:00 Featured Presentation 

Arrayed Antibody Libraries for Direct Cell-Based Discovery

Vaughn SmiderVaughn Smider, M.D., Ph.D., Assistant Professor, Molecular Biology, Scripps Research Institute; Founder, Fabrus LLC - Biography

Antibody discovery typically requires purified protein to be used for immunization or selection of a display based library. We have generated a spatially addressed library with a single synthetic germline antibody per microtiter well. These libraries were directly screened against target cells by high-throughput FACS to obtain specific hits against antigens in their native cellular context. This format could pave the way to antibody discovery against previously intractable targets that can only be expressed in cells.

9:30 Step 1: Probing the Biology in the IgG Discovery Process

Michael FeldhausMichael J. Feldhaus, Ph.D., Executive Vice President, Research, Adimab, LLC - Biography

Many a researcher has dreamt of an antibody discovery platform that allows the user to simply "add the target" and rapidly generate IgGs that have their desired therapeutically relevant biology. Adimab has brought the dream closer to reality. First, broad epitopic coverage is enabled through utilizing natural human IgG diversity from 20 different VH germline libraries. Second, selections take weeks with the output being an IgG which allows expression, biology, and even Pk properties of the IgG to be assessed. Last, a variety of facile and robust optimization approaches allows functional IgGs to be "fine-tuned" into low picomolar affinities, or other desired properties. Case studies representing each of these aspects will be presented.

10:00 Networking Coffee Break in the Exhibit Hall, Poster Viewing


Antibody Discovery & Optimization 

10:45 Discovery & Optimization of XB 2202, a Potent, Stable, Soluble Anti-RTK VH Domain Implicated in Angiogenesis, by dsDNA Display and Deep Sequencing

Richard WagnerRichard Wagner, Ph.D., Founder & CSO, R & D, X-BODY BioSciences - Biography

We describe a platform for generating and optimizing hMABs under mammalian folding conditions by dsDNA display of fully human libraries. Sequencing of thousands of hits provides an early read on the function, affinity and specificity of lead candidates. We have affinity matured these VH domains using a rapid framework optimization that maintains their fully human character. A novel VL pairing method has been used to construct fully human scFv and IgG with the biological functional activity that was predicted by deep sequencing.

11:15 Creation of Novel Antibody Properties and Activities with Fc Engineering

J DesjarlaisJohn Desjarlais, Ph.D., Vice President, Research, Xencor, Inc. - Biography

The Fc domain of antibodies carries a number of intrinsic properties that can be enhanced via protein engineering to improve on existing antibodies or to create antibodies with novel biological activities.  Improving interactions with activating Fc receptors heightens effector function for application in oncology and other areas, and early clinical data suggests that such modifications improve therapeutic efficacy.  Enhancing interactions with FcRn increases in vivo half-life, and the modular application of this platform yields a new pipeline of longer-acting biosuperiors such as Xtend-TNF and Xtend-CTLA4.  Finally, our recent discovery of Fc mutations that increase binding to the inhibitor receptor CD32b has led to the creation of antibodies with completely novel mechanisms of action, including the ability to selectively inhibit different B cell populations without depletion.

11:45 Glycooptimized Second Generation Antibodies for Cancer Treatment

Steffen GoletzSteffen Goletz, Ph.D., CEO, Glycotope GmbH - Biography

Antibodies of the 21st century require reduced immunogenicity for limited unwanted side effects and optimized serum half-life for improved bioavailability. Furthermore, reproducibility and high productivity is a major prerequisite for up-to-date production processes with optimized Fc effector function for highest patient coverage. We will present novel production technologies as well as preclinical and clinical data for antibodies that meet these criteria.

12:15 pm Close of Morning Session

Sponsored by
12:30 Luncheon Presentation
Biotherapeutic De-Risking: Avoiding and Reducing Immunogenicity and Aggregates
Philippe Stas Philippe Stas, MBA, Head of Applied Protein Services, Lonza AG - Biography
Most protein therapeutics are to a variable extent immunogenic. In some cases, this immunogenicity has no effect on the efficacy of the drug or tolerance in the patient, however, it can in certain cases lead to loss of efficacy (due to ADA responses)  or even to severe side effects; both of which will impact FiM trials. This session will present strategies to identify and mitigate the immunogenicity risk before entering the clinic. Special attention will be given to the most recent regulatory and industry guidelines. Case studies will be presented using the Epibase Immunogenicity Assessment Platform in pre-clinical drug development.  


Computational Technologies & Analytical Insights 

2:00 Chairperson's Remarks

Michael J. Feldhaus, Ph.D., Executive Vice President, Research, Adimab, LLC

2:05 Enhanced Therapeutic Antibody Discovery Using Deep Sequencing

Nicolas FischerNicolas Fischer, Ph.D., Head, Research Department, NovImmune SA - Biography

Using the Illumina platform for Deep Sequencing of the initial collection and of the enriched fractions, we could obtain a global view of the evolution of virtually all antibody sequences throughout the enrichment process and bypass the screening step by selecting candidates based on the sequencing information. Importantly, candidates that were missed by the screening process could be identified in silico. The implications of this approach for standard as well as next generation antibody discovery will be discussed.

2:35 Fighting Disease by Designed Monoclonal Antibodies

Samuel FloresSamuel Flores, Ph.D., Assistant Professor, Cell and Molecular Biology, Uppsala University - Biography

Viruses change from season to season and adapt quickly to antibodies, and so the long wet-lab development times must be shortened with intelligent computational design techniques. Computational modeling of macromolecules has made considerable progress in recent years as multiresolution methods sidestep much of the cost of simulation, concentrating resources on the region of interest while reducing the degrees of freedom elsewhere. Following this approach, we design monoclonal antibodies by computing physical interactions in the interface between antibody and antigen. We compare computational against experimental results using well characterized test cases.

3:05 PK and ADME Studies of Therapeutic Antibodies and Proteins

Y VugmeysterYulia Vugmeyster, Ph.D., Senior Principal Scientist, Drug Safety & Metabolism, Pfizer Research Labs - Biography

Rational engineering of desired PK and ADME profile is becoming an increasingly important aspect of commercial development. In this talk, I will present a number of case studies that highlight advances and challenges in our understanding of PK and ADME profiles of therapeutic proteins, including translation from animals to humans.

Engineered Monoclonal Auto-Antibodies from the B Cell Repertoire of Patients Affected by Scleroderma Highlight the Map of PDGF Receptor Epitopes Involved in Pro-Fibrotic Signaling, Poster B306

Gianluca Moroncini, Ph.D., Associate Faculty Member, Clinical & Molecular Science, Università Politecnica delle Marche

3:50 Networking Refreshment Break


Moving Antibody Therapeutics into the Clinic 

4:30 Beyond Blocking: The New Frontier in Antibody Engineering

Marina Roell, Ph.D., Director, Molecular Interactions & Research Informatics, XOMA (US) LLC

Most pathways that have been linked to disease when abnormally regulated have important roles in healthy tissues, so that attenuation, rather than complete blocking or activation, of signaling pathways may provide a superior approach to restore a normal physiological state. The anti-IL-1beta antibody, XOMA 052 (gevokizumab), is an example of an antibody with such a regulatory mechanism of action. In addition, anti-Insulin Receptor antibodies have been engineered that regulate activation of the insulin receptor by modulating the affinity of insulin binding.

5:00 cGMP Compliant Production of a Monoclonal Antibody Manufactured from GM Plants

Y VugmeysterJulian K.C. Ma, Ph.D., Professor, Hotung Chair, Molecular Immunology, Joint Head, Infection and Immunity Research Centre, St. Georges Hospital Medical Center - Biography

Plants have been proposed as an economic and highly scalable production system for recombinant proteins for many years. Compared to the industry standard of mammalian or bacterial cell fermentation, however, there has always been doubt that a high quality, reproducible manufacturing process that is compliant with cGMP was achievable. This talk will discuss the pre-clinical development of a monoclonal antibody drug product derived from genetically modified tobacco plants, its recent regulatory approval and the subsequent Phase I clinical trial.

5:30 - 6:30 Reception in the Exhibit Hall with Poster Viewing


Day 1 | Day 2 | Download Brochure 

Links to Companion Meetings

Pipeline 1 

Bispecific Antibody Therapeutics 

Recombinant Protein Therapeutics